Back To: Home : Featured Technology : Reagents/Proteins


MorphoSys and FMP sign broad research partnership
May 2008

MARTINSRIED, Germany—MorphoSys AG recently announced a broad alliance with the Leibniz-Institut fur Molekulare Pharmakologie (FMP), Berlin, covering the use of fully human recombinant research antibodies and commercialization of resulting products. Under the terms of the agreement, the FMP will receive access to novel HuCAL GOLD-based research antibodies from MorphoSys's AbD Serotec unit to identify and validate target molecules with potential medical applications. MorphoSys retains commercialization rights for all antibodies emerging from the collaboration both as research antibody tools distributed via the AbD Serotec sales catalogue as well as in therapeutic or diagnostic applications. Financial details of the agreement were not disclosed.

"We are looking forward very much to cooperating with MorphoSys," says Walter Rosenthal, director of FMP. "This kind of public-private partnership provides us with the perfect tools to study the proteins we are working on in order to elucidate their function and to evaluate their potential as drug targets. We are proud to be the first German scientific institution that holds such a cooperation with MorphoSys—strong support for our efforts to open new ways to transfer scientific results into therapy."

Research at FMP focuses on the structures, functions and interactions of proteins and on the development of new concepts for interfering pharmacologically with their functions. An interdisciplinary approach is crucial to this type of work, and a particular strength of the FMP is the close interaction in the fields of chemistry and biology.



1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.